0001225208-23-005593.txt : 20230508
0001225208-23-005593.hdr.sgml : 20230508
20230508215411
ACCESSION NUMBER: 0001225208-23-005593
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230505
FILED AS OF DATE: 20230508
DATE AS OF CHANGE: 20230508
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BOBO DONALD E JR
CENTRAL INDEX KEY: 0001196661
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15525
FILM NUMBER: 23899729
MAIL ADDRESS:
STREET 1: C/O EDWARDS LIFESCIENCES
STREET 2: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edwards Lifesciences Corp
CENTRAL INDEX KEY: 0001099800
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
IRS NUMBER: 364316614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
BUSINESS PHONE: 9492502500
MAIL ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP.
DATE OF NAME CHANGE: 20090225
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP
DATE OF NAME CHANGE: 20000203
FORMER COMPANY:
FORMER CONFORMED NAME: CVG CONTROLLED INC
DATE OF NAME CHANGE: 19991126
4
1
doc4.xml
X0407
4
2023-05-05
0001099800
Edwards Lifesciences Corp
EW
0001196661
BOBO DONALD E JR
ONE EDWARDS WAY
IRVINE
CA
92614
1
CVP,Strategy/Corp Development
0
Common Stock
2023-05-05
4
S
0
5635.0000
88.6250
D
56224.6931
D
Common Stock
2023-05-07
4
M
0
4767.0000
0
A
60991.6931
D
Common Stock
2023-05-07
4
F
0
2968.0000
88.7400
D
58023.6931
D
Common Stock
2023-05-08
4
F
0
1399.0000
88.7400
D
56624.6931
D
Common Stock
38444.3700
I
401(k)
Common Stock
111605.0000
I
By Trust
Performance Rights
2023-05-07
4
M
0
4767.0000
0.0000
D
2023-05-07
2027-05-06
Common Stock
4767.0000
1308.0000
D
On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact
2023-05-08